2021
Impact of COVID-19 on gastroenterology fellowship training: a multicenter analysis of endoscopy volumes
Paleti S, Sobani ZA, McCarty TR, Gutta A, Gremida A, Shah R, Nutalapati V, Bazerbachi F, Jesudoss R, Amin S, Okwara C, Kathi PR, Ahmed A, Gessel L, Hung K, Masoud A, Yu J, Mony S, Akshintala V, Jamil L, Nasereddin T, Kochhar G, Vyas N, Saligram S, Garg R, Sandhu D, Benrajab K, Konjeti R, Agnihotri A, Trivedi H, Grunwald M, Mayer I, Mohanty A, Rustagi T. Impact of COVID-19 on gastroenterology fellowship training: a multicenter analysis of endoscopy volumes. Endoscopy International Open 2021, 09: e1572-e1578. PMID: 34540553, PMCID: PMC8445682, DOI: 10.1055/a-1526-1419.Peer-Reviewed Original ResearchGastroenterology fellowship programsEndoscopy volumeProcedure volumeUpper endoscopyLower endoscopyStudy period 1Study period 2COVID-19Gastroenterology fellowship trainingElectronic medical recordsFellowship programsMulticenter analysisMulticenter studyMedical recordsLesser proceduresGastroenterology training programsGastroenterology fellowsEndoscopy
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis